세계의 동물용 생물학적 제제 시장 보고서(2025년)

Veterinary biologics encompass biological products obtained from living organisms such as viruses, bacteria, or other microorganisms. These specialized products in veterinary medicine serve to prevent, diagnose, or treat diseases in animals.

Key products falling under veterinary biologics include vaccines, diagnostic kits, immunomodulators, antiserums, antibodies, and related items. Vaccines, for instance, are formulated to trigger the immune system's response and offer protection against specific animal diseases. They address various ailments such as bluetongue, foot and mouth disease, brucellosis, tuberculosis, and others. These products are distributed through multiple channels, including veterinary hospitals and clinics, for diverse applications involving both production and companion animals.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a considerable impact on the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care products. Increased duties on imported veterinary medicines, diagnostic equipment, surgical tools, and pet care supplies have driven up operational costs for veterinary clinics, animal hospitals, and livestock health providers, forcing them to either raise service charges or absorb reduced profit margins. The livestock and agricultural industries are facing similar pressures, as tariffs on feed additives, vaccines, and breeding equipment push up production costs and complicate animal health management. Furthermore, retaliatory tariffs in major export markets have weakened demand for U.S.-manufactured veterinary products, adding to revenue challenges. To navigate these headwinds, the sector must now focus on local sourcing, preventive healthcare strategies, and digital veterinary solutions to control costs while continuing to deliver quality animal care.

The veterinary biologics market research report is one of a series of new reports from The Business Research Company that provides veterinary biologics market statistics, including veterinary biologics industry global market size, regional shares, competitors with a veterinary biologics market share, detailed veterinary biologics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary biologics industry. This veterinary biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The veterinary biologics market size has grown strongly in recent years. It will grow from $12.67 billion in 2024 to $13.61 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to animal disease outbreaks, regulatory support and standards, demand for food safety, globalization of trade, and economic significance of livestock.

The veterinary biologics market size is expected to see strong growth in the next few years. It will grow to $18.36 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to emerging infectious diseases, climate change and disease patterns, precision livestock farming, one health approach, and increased pet ownership trends. Major trends in the forecast period include education and training programs, eco-friendly and sustainable biologics, integration of digital health records, rise in companion animal biologics, and customized and targeted therapies.

The forecast of 7.8% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade barriers on critical biologic inputs, such as recombinant proteins and cell lines, could hinder production scalability and delay veterinary biologics development timelines. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The upsurge in the prevalence of animal diseases is anticipated to be a driving force behind the growth of the veterinary biologics market. Animal diseases encompass a range of illnesses affecting diverse animal species. The escalation in these diseases underscores the need for advanced diagnostic and treatment solutions, a demand met by veterinary biologics that employ immunological methods to address and manage animal diseases. As of October 2022, the European Center for Disease Prevention and Control reported 2,467 outbreaks of avian influenza in poultry, impacting 48 million birds, with an additional 187 cases observed in captive birds. In a related context, the World Health Organization disclosed in July 2022 that rabies claims the lives of 59,000 people annually across over 150 countries, with a predominant 95% of cases concentrated in Africa and Asia. This surge in animal diseases is a pivotal factor propelling the veterinary biologics market.

The increasing trend of pet adoption is poised to contribute significantly to the growth of the veterinary biologics market. Pet adoption involves assuming responsibility for a domesticated animal, often from shelters or rescue organizations, to provide a permanent and caring home. Veterinary biologics play a crucial role in preventing infectious diseases in pets, offering immunity, controlling zoonotic diseases, enhancing lifespan and quality of life, reducing veterinary healthcare costs, improving reproductive health in pets, and providing more targeted and customized treatment options. Data from October 2023, as reported by the American Pet Products Association, reveals that 66% of U.S. households, totaling 86.9 million, own a pet-an increase from 62% in 2022. This surge in pet adoption is a significant driver behind the expanding veterinary biologics market.

Leading companies in the veterinary biologics market are concentrating on the development of innovative biologics, such as vaccines, to improve animal health and prevent diseases. A vaccine is a substance that triggers the immune system to recognize and combat specific pathogens, helping to prevent infectious diseases by providing acquired immunity. For example, in August 2024, Merck Animal Health, a global animal health company based in the U.S., launched an experimental autogenous vaccine targeting avian metapneumovirus (aMPV) type B, which received approval from the U.S. Department of Agriculture (USDA) for manufacturing and sale. Created in partnership with Cambridge Technologies, this vaccine aims to address the serious respiratory problems caused by aMPV type B in poultry, which have resulted in significant economic losses since late 2023. Manufactured at a state-of-the-art facility in Minnesota, the vaccine uses an oil and water emulsion formulation designed to reduce post-vaccination tissue reactions, filling a crucial gap in the market as there were previously no commercially licensed vaccines available.

Companies at the forefront of the veterinary biologics market are also channeling their efforts into the creation of innovative products, such as injections designed to control pain associated with osteoarthritis (OA) in dogs. These injections target canine nerve growth factors, providing an effective means to alleviate the pain that dogs experience due to osteoarthritis. Zoetis Inc., a distinguished U.S.-based animal health company, secured approval from the U.S. Food and Drug Administration (FDA) for Librela (bedinvetmab injection) in May 2023. Positioned as the first and only monthly anti-NGF monoclonal antibody medication for canine OA pain, Librela stands out as a safe and efficacious solution for managing long-term OA pain symptoms in dogs. This approval underscores Librela's role in enhancing the mobility and overall well-being of canines grappling with osteoarthritis, contributing to an improved quality of life for these animals.

In January 2024, Ceva Sante Animale, a pharmaceutical company based in France, acquired Scout Bio for an undisclosed amount. This acquisition enhances Ceva's biotechnology capabilities and speeds up its innovation in pet therapeutics, particularly targeting advanced treatments for chronic diseases. This strategic move responds to the growing demand for better health solutions among pet owners. Scout Bio is a biotechnology company located in the U.S. that specializes in providing essential data for the development of effective veterinary biologics, including vaccines and diagnostics.

Major companies operating in the veterinary biologics market include Bayer AG, Eli Lilly & Company, Evonik Industries AG, Zoetis Inc., Merck Animal Health Inc., Boehringer Ingelheim Animal Health Inc., Elanco Animal Health, IDEXX Laboratories Inc., Virbac SA, Phibro Animal Health Corporation, Vetoquinol, Abaxis Inc., Bimeda Biologicals, Ceva Sante Animale S.A., Heska Corporation, Colorado Serum Company, Hester Biosciences Limited, INDICAL Bioscience GmbH, Ambrx Biopharma Inc., Adamis Pharmaceuticals Corporation, Intervet Inc., Hebei Veyong Animal Pharmaceutical Co. Ltd., FidoCure, Biomet Biologics LLC, CytoDyn Veterinary Medicine LLC, KM Biologics

North America was the largest region in the veterinary biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the veterinary biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The veterinary biologics market consists of sales of transplant tissues, recombinant proteins, and stem cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Veterinary Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on veterinary biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for veterinary biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The veterinary biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Vaccines; Diagnostic Kits; Immunomodulators; Antiserums And Antibodies; Other Products
• 2) By Disease Type: Bluetongue; Foot And Mouth Disease; Brucellosis And Tuberculosis; Other Diseases
• 3) By Distribution Channel: Veterinary Hospitals; Veterinary Clinics; Other Distribution Channels
• 4) By Application: Production Animal; Companion Animal
• Subsegments:
• 1) By Vaccines: Live Attenuated Vaccines; Inactivated Vaccines; Recombinant Vaccines; DNA Vaccines
• 2) By Diagnostic Kits: Rapid Tests; Elisa Kits; Pcr-Based Diagnostic Kits
• 3) By Immunomodulators: Cytokines; Adjuvants; Immunostimulants
• 4) By Antiserums And Antibodies: Monoclonal Antibodies; Polyclonal Antibodies; Hyperimmune Serums
• 5) By Other Products: Probiotics; Prebiotics; Growth Factors; Toxoids
• Companies Mentioned: Bayer AG; Eli Lilly & Company; Evonik Industries AG; Zoetis Inc.; Merck Animal Health Inc.; Boehringer Ingelheim Animal Health Inc.; Elanco Animal Health; IDEXX Laboratories Inc.; Virbac SA; Phibro Animal Health Corporation; Vetoquinol; Abaxis Inc.; Bimeda Biologicals; Ceva Sante Animale S.A.; Heska Corporation; Colorado Serum Company; Hester Biosciences Limited; INDICAL Bioscience GmbH; Ambrx Biopharma Inc.; Adamis Pharmaceuticals Corporation; Intervet Inc.; Hebei Veyong Animal Pharmaceutical Co. Ltd.; FidoCure; Biomet Biologics LLC; CytoDyn Veterinary Medicine LLC; KM Biologics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Veterinary Biologics Market Characteristics

3. Veterinary Biologics Market Trends And Strategies

4. Veterinary Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Veterinary Biologics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Veterinary Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Veterinary Biologics Market Growth Rate Analysis
• 5.4. Global Veterinary Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Veterinary Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Veterinary Biologics Total Addressable Market (TAM)

6. Veterinary Biologics Market Segmentation

• 6.1. Global Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vaccines
• Diagnostic Kits
• Immunomodulators
• Antiserums And Antibodies
• Other Products
• 6.2. Global Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bluetongue
• Foot And Mouth Disease
• Brucellosis And Tuberculosis
• Other Diseases
• 6.3. Global Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Veterinary Hospitals
• Veterinary Clinics
• Other Distribution Channels
• 6.4. Global Veterinary Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Production Animal
• Companion Animal
• 6.5. Global Veterinary Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Vaccines
• Inactivated Vaccines
• Recombinant Vaccines
• DNA Vaccines
• 6.6. Global Veterinary Biologics Market, Sub-Segmentation Of Diagnostic Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rapid Tests
• Elisa Kits
• Pcr-Based Diagnostic Kits
• 6.7. Global Veterinary Biologics Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytokines
• Adjuvants
• Immunostimulants
• 6.8. Global Veterinary Biologics Market, Sub-Segmentation Of Antiserums And Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Polyclonal Antibodies
• Hyperimmune Serums
• 6.9. Global Veterinary Biologics Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Probiotics
• Prebiotics
• Growth Factors
• Toxoids

7. Veterinary Biologics Market Regional And Country Analysis

• 7.1. Global Veterinary Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Veterinary Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Veterinary Biologics Market

• 8.1. Asia-Pacific Veterinary Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Veterinary Biologics Market

• 9.1. China Veterinary Biologics Market Overview
• 9.2. China Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Veterinary Biologics Market

• 10.1. India Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Veterinary Biologics Market

• 11.1. Japan Veterinary Biologics Market Overview
• 11.2. Japan Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Veterinary Biologics Market

• 12.1. Australia Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Veterinary Biologics Market

• 13.1. Indonesia Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Veterinary Biologics Market

• 14.1. South Korea Veterinary Biologics Market Overview
• 14.2. South Korea Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Veterinary Biologics Market

• 15.1. Western Europe Veterinary Biologics Market Overview
• 15.2. Western Europe Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Veterinary Biologics Market

• 16.1. UK Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Veterinary Biologics Market

• 17.1. Germany Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Veterinary Biologics Market

• 18.1. France Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Veterinary Biologics Market

• 19.1. Italy Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Veterinary Biologics Market

• 20.1. Spain Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Veterinary Biologics Market

• 21.1. Eastern Europe Veterinary Biologics Market Overview
• 21.2. Eastern Europe Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Veterinary Biologics Market

• 22.1. Russia Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Veterinary Biologics Market

• 23.1. North America Veterinary Biologics Market Overview
• 23.2. North America Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Veterinary Biologics Market

• 24.1. USA Veterinary Biologics Market Overview
• 24.2. USA Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Veterinary Biologics Market

• 25.1. Canada Veterinary Biologics Market Overview
• 25.2. Canada Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Veterinary Biologics Market

• 26.1. South America Veterinary Biologics Market Overview
• 26.2. South America Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Veterinary Biologics Market

• 27.1. Brazil Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Veterinary Biologics Market

• 28.1. Middle East Veterinary Biologics Market Overview
• 28.2. Middle East Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Veterinary Biologics Market

• 29.1. Africa Veterinary Biologics Market Overview
• 29.2. Africa Veterinary Biologics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Veterinary Biologics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Veterinary Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Veterinary Biologics Market Competitive Landscape And Company Profiles

• 30.1. Veterinary Biologics Market Competitive Landscape
• 30.2. Veterinary Biologics Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly & Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Zoetis Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck Animal Health Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Veterinary Biologics Market Other Major And Innovative Companies

• 31.1. Boehringer Ingelheim Animal Health Inc.
• 31.2. Elanco Animal Health
• 31.3. IDEXX Laboratories Inc.
• 31.4. Virbac SA
• 31.5. Phibro Animal Health Corporation
• 31.6. Vetoquinol
• 31.7. Abaxis Inc.
• 31.8. Bimeda Biologicals
• 31.9. Ceva Sante Animale S.A.
• 31.10. Heska Corporation
• 31.11. Colorado Serum Company
• 31.12. Hester Biosciences Limited
• 31.13. INDICAL Bioscience GmbH
• 31.14. Ambrx Biopharma Inc.
• 31.15. Adamis Pharmaceuticals Corporation

32. Global Veterinary Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Veterinary Biologics Market

34. Recent Developments In The Veterinary Biologics Market

35. Veterinary Biologics Market High Potential Countries, Segments and Strategies

• 35.1 Veterinary Biologics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Veterinary Biologics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Veterinary Biologics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer